Should we edit human embryos' genomes, and if so then how?
By Dieter Egli,
BioNews [cites CGS' Marcy Darnovsky]
| 07. 12. 2021
I recently received a thoughtful letter from a college student I do not know – I'll call her Claudia* – who took the time to reach out to me with her perspective on heritable genome editing in embryos. The promise of this new technology is that it could fix disease-causing mutations in all cells of the body before damage occurs, and the correction would be passed on to future generations as well.
My laboratory at Columbia University, New York performs basic research to better understand early human development with the goal of benefiting patients with heritable diseases. Last fall, we published an article in Cell about using CRISPR/Cas9 to potentially correct a blindness-causing mutation in embryos; we discovered that the use of this technology could lead to unintended loss of additional genetic material. Our findings were discussed in national and international media, and had apparently caught Claudia's attention. I reference Claudia's letter here, as I believe that many people share the hopes and concerns she expressed, and because they also in fact align with my own scientific views.
My...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Antonio Regalado, MIT Technology Review | 10.31.2025
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology.
The new company, called Preventive, is...